Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS
6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS
7.1.2 RISE IN THE GERIATRIC POPULATION
7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS
7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS
7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS
7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS
7.2.3 EMERGENCE OF GENERICS
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S.
7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS
7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE
7.4 CHALLENGES
7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER
7.4.2 STRINGENT REGULATORY LANDSCAPE
7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE
8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 INSOMNIA
9.2.1 INSOMNIA
9.2.2 CHILD INSOMNIA
9.2.3 OTHERS
9.3 SLEEP APNEA
9.3.1 OBSTRUCTIVE SLEEP APNEA
9.3.2 CENTRAL SLEEP APNEA
9.3.3 SNORING
9.3.4 INFANT SLEEP APNEA
9.3.5 OTHERS
9.4 RESTLESS LEGS SYNDROME (RLS)
9.5 NARCOLEPSY
9.5.1 TYPE 1
9.5.2 TYPE 2
10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PHARMACOLOGICAL THERAPY
10.2.1 CANNABIDIOL
10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)
10.2.3 BENZODIAZEPINES
10.2.4 NON-BENZODIAZEPINE
10.2.5 MELATONIN RECEPTOR STIMULATOR
10.2.6 STIMULANTS
10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
10.2.8 TRICYCLIC ANTIDEPRESSANTS
10.2.9 SODIUM OXYBATE (XYREM)
10.2.10 OTHERS
10.3 MECHANICAL THERAPY
10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)
10.3.2 BI-LEVEL PAP
10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP
10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)
10.4 MANDIBULAR ADVANCEMENT DEVICES
10.5 HYPOGLOSSAL NERVE STIMULATOR
10.6 SURGERY
10.6.1 SOMNOPLASTY
10.6.2 TONSILLECTOMY
10.6.3 NASAL SURGERY
10.6.4 OTHERS
10.7 OTHERS
11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 PILLS
11.2.3 OTHERS
11.3 PARENTERAL
11.4 OTHERS
12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 XYREM
12.3.2 EFFEXOR XR
12.3.3 AMBIEN
12.3.4 PRISTIQ
12.3.5 ZENZEDI
12.3.6 VYVANSE
12.3.7 OTHERS
13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULT
13.3 CHILDREN
14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 AMBULATORY SURGICAL CENTER
14.6 OTHERS
15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JAZZ PHARMACEUTICALS, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 ELI LILLY AND COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 VIATRIS INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 RESMED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MALLINCKRODT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 KONINKLIJKE PHILIPS N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALEMBIC PHARMACEUTICALS LIMITED
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 AMNEAL PHARMACEUTICALS LLC
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 APOTEX INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 ARBOR PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 BMC MEDICAL CO.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 DEVILBISS HEALTHCARE LLC
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.15 DR. REDDY’S LABORATORIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HIKMA PHARMACEUTICALS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 OVENTUS
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SOMNOMED
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 TAJ PHARMACEUTICALS LIMITED
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT
TABLE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 6 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 9 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 10 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 11 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 U.S. SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 U.S. NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2019-2028 (USD MILLION)
TABLE 38 U.S. SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 39 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)
TABLE 40 U.S. MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 41 U.S. SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 42 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 U.S. ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 45 U.S. BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 47 U.S. SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 U.S. SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 CANADA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 CANADA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 CANADA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 CANADA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 53 CANADA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 54 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 55 CANADA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 56 CANADA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 57 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 58 CANADA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 60 CANADA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 61 CANADA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 62 CANADA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CANADA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MEXICO SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 68 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 69 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 70 MEXICO MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 71 MEXICO SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 72 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 MEXICO ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 75 MEXICO BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 76 MEXICO SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 77 MEXICO SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 MEXICO SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 10 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
FIGURE 13 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 14 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020
FIGURE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 21 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)
FIGURE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 25 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 27 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020
FIGURE 29 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)
FIGURE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020
FIGURE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 35 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020
FIGURE 37 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 45 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 46 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)
FIGURE 49 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)
